Trial Profile

A phase 1/2 study of Recombinant-collagen in Recombinant-collagen

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant collagen (Primary)
Indications Dupuytren's contracture
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use

07 May 2025 According to a Connext media release, The dose expansion (Phase 2) part is scheduled to begin in Q3 2025 as a double-blind study, aiming to demonstrate statistically significant efficacy. Top-line data for the entire Phase 1/2 trial are expected in the first half of 2026, with plans to initiate global Phase 3 development in 2027.
07 May 2025 According to a Connext media release, company announced the successful completion of the dose escalation (Phase 1) part of its Phase 1/2 clinical trial for CNT201, its recombinant collagenase therapeutic for Dupuytren's contracture.
30 Jul 2024 According to a Connext media release, Phase 1 part of the Phase 1/2 trial, conducted across three hospitals.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com